CEACAM5 and urokinase-type plasminogen activator measurement: MD-IPMNs: main duct intraductal papillary mucinous neoplasms of the pancreas; FPPA: focal pancreatic parenchymal atrophy; UPA: upper pancreatic atrophy; AMY: serum amylase levels; LIP: serum lipase levels; CA19-9: serum carbohydrate antigen 19-9 levels; CEA: serum carcinoembryonic antigen levels; Ph: pancreatic head; Pbt: pancreatic body and tail; MPD: main pancreatic duct; MN: mural nodule.